Search
Phycomyces blakesleeanus
go.drugbank.com/drugs/DB10845ApprovedPhycomyces blakesleeanus extract is used in allergenic testing.
Mixtures: Treatment Set TS128871Sporotrichum pruinosum
go.drugbank.com/drugs/DB10846ApprovedSporotrichum pruinosum extract is used in allergenic testing.
Mixtures: Treatment Set TS128871Stachybotrys chartarum
go.drugbank.com/drugs/DB10847ApprovedStachybotrys chartarum extract is used in allergenic testing.
Mixtures: Treatment Set TS128871Syncephalastrum racemosum
go.drugbank.com/drugs/DB10848ApprovedSyncephalastrum racemosum extract is used in allergenic testing.
Mixtures: Treatment Set TS128871Quinine
go.drugbank.com/drugs/DB00468ApprovedInvestigationalIt is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. … It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis.
Products: QUININE SULPHATE TABLETS 300 mgCenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalIt received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … [L4563] In particular, cenegermin was granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines
Naratriptan
go.drugbank.com/drugs/DB00952ApprovedIt is typically used for the treatment of migraine headaches.
Synonyms: N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide, N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamideProducts: NARAMIG TABLETS 2.5 mg, NARAMIG TABLETAS 2.5 MGMethyl undecenoyl leucinate
go.drugbank.com/drugs/DB11272ApprovedIt is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes. … Methyl undecenoyl leucinate is an active ingredient in whitening creams.
Methyprylon
go.drugbank.com/drugs/DB01107ApprovedIllicitWithdrawnMethyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.